Overview

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Participants will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Phase:

Phase 3

Details

Lead Sponsor:

Genentech, Inc.

Collaborator:

Hoffmann-La Roche

Treatments:

Antibodies, Monoclonal
Erlotinib Hydrochloride